Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics


Fennec Pharmaceuticals Inc. (FENC): $5.71

0.13 (+2.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FENC POWR Grades


  • Growth is the dimension where FENC ranks best; there it ranks ahead of 97.6% of US stocks.
  • FENC's strongest trending metric is Growth; it's been moving up over the last 178 days.
  • FENC's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

FENC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FENC is 0.01 -- better than merely 6.95% of US stocks.
  • FENC's price/sales ratio is 778.68; that's higher than the P/S ratio of 99.3% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for Fennec Pharmaceuticals Inc; that's greater than it is for only 12.15% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Fennec Pharmaceuticals Inc, a group of peers worth examining would be BFLY, ARLO, NTNX, MOTS, and DMRC.
  • FENC's SEC filings can be seen here. And to visit Fennec Pharmaceuticals Inc's official web site, go to www.fennecpharma.com.

FENC Valuation Summary

  • In comparison to the median Healthcare stock, FENC's price/earnings ratio is 130.96% lower, now standing at -11.3.
  • FENC's price/earnings ratio has moved down 3.7 over the prior 203 months.
  • FENC's price/sales ratio has moved NA NA over the prior 203 months.

Below are key valuation metrics over time for FENC.

Stock Date P/S P/B P/E EV/EBIT
FENC 2021-08-31 1211.8 9.2 -11.3 -10.1
FENC 2021-08-30 1202.4 9.2 -11.2 -10.0
FENC 2021-08-27 1247.1 9.5 -11.7 -10.4
FENC 2021-08-26 1219.4 9.3 -11.4 -10.2
FENC 2021-08-25 1222.4 9.3 -11.4 -10.2
FENC 2021-08-24 1181.2 9.0 -11.0 -9.8

FENC Growth Metrics

    The 4 year price growth rate now stands at 142.31%.
  • Its year over year net cashflow from operations growth rate is now at -49.46%.
  • Its year over year net income to common stockholders growth rate is now at -36.07%.
Over the past 33 months, FENC's revenue has gone up $170,000.

The table below shows FENC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0.17 -14.261 -16.157
2021-06-30 0.17 -16.749 -18.172
2021-03-31 0.17 -15.439 -19.016
2020-12-31 0.17 -15.595 -18.109
2020-09-30 0 -13.901 -18.481
2020-06-30 0 -10.69 -14.09

FENC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FENC has a Quality Grade of D, ranking ahead of 21.94% of graded US stocks.
  • FENC's asset turnover comes in at 0.006 -- ranking 405th of 680 Pharmaceutical Products stocks.
  • AUPH, APLS, and CARA are the stocks whose asset turnover ratios are most correlated with FENC.

The table below shows FENC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.006 1 642.938
2021-03-31 0.005 1 9.909
2020-12-31 0.006 1 9.925
2020-09-30 0.000 NA 9.479
2020-06-30 0.000 NA 9.306
2020-03-31 0.000 NA 12.541

FENC Price Target

For more insight on analysts targets of FENC, see our FENC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.60 Average Broker Recommendation 1.4 (Strong Buy)

FENC Stock Price Chart Interactive Chart >

Price chart for FENC

FENC Price/Volume Stats

Current price $5.71 52-week high $6.55
Prev. close $5.58 52-week low $3.20
Day low $5.53 Volume 35,700
Day high $5.81 Avg. volume 37,495
50-day MA $5.72 Dividend yield N/A
200-day MA $5.08 Market Cap 148.80M

Fennec Pharmaceuticals Inc. (FENC) Company Bio


Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.


FENC Latest News Stream


Event/Time News Detail
Loading, please wait...

FENC Latest Social Stream


Loading social stream, please wait...

View Full FENC Social Stream

Latest FENC News From Around the Web

Below are the latest news stories about Fennec Pharmaceuticals Inc that investors may wish to consider to help them evaluate FENC as an investment opportunity.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - FENC

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the "Class Period") of the important April 11, 2022…

PR Newswire | February 18, 2022

Kirby McInerney LLP Investors That a Class Action Lawsuit Has Been Filed on Behalf of Fennec Pharmaceuticals Inc. (FENC) Investors and Encourages Investors to Contact the Firm Before April 11, 2022

NEW YORK--(BUSINESS WIRE)---- $FENC--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities from May 28, 2021 to November 26, 2021 inclusive (the “Class Period”). Investors have until April 11, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Fennec is a b

Business Wire | February 18, 2022

FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fennec investors who were…

PR Newswire | February 17, 2022

ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – FENC

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”) of the important April 11, 2022 lead plaintiff deadline .

GlobeNewswire | February 16, 2022

FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 11, 2022 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Shareholders

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) alleging that the Company violated federal securities laws. Class Period: May 28, 2021 to November 26,…

PR Newswire | February 15, 2022

Read More 'FENC' Stories Here

FENC Price Returns

1-mo -0.17%
3-mo -3.22%
6-mo 26.33%
1-year 58.61%
3-year 187.66%
5-year N/A
YTD 29.77%
2021 18.12%
2020 14.79%
2019 1.72%
2018 -36.33%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6772 seconds.